Literature DB >> 21859690

Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis.

Erika Darrah1, Antony Rosen, Jon T Giles, Felipe Andrade.   

Abstract

OBJECTIVE: To define the relationship between autoantigen citrullination and different peptidylarginine deiminase (PAD) enzymes in rheumatoid arthritis (RA).
METHODS: Citrullinated autoantigens were identified by immunoblotting control and ionomycin-activated human primary neutrophil lysate with RA sera. Autoantigen identity and citrullination sites were defined by mass spectrometry. PAD isoenzyme expression in human neutrophils was determined by immunoblotting. PAD substrate specificity was addressed in HL-60 cell lysates co-incubated with human recombinant PAD2, PAD3 and PAD4.
RESULTS: Although prominent protein citrullination is observed in ionomycin-activated neutrophils, RA sera only recognised a limited number of these citrullinated molecules. Among these, the authors identified that β and γ-actins are citrullinated on at least 10 arginine residues, generating a novel 47 kDa species that is frequently recognised by RA autoantibodies. Interestingly, the authors showed that the PAD enzymes expressed in human neutrophils (ie, PAD2, PAD3 and PAD4) have unique substrate specificities, independent of their subcellular distribution. Thus, only PAD2 was able to citrullinate native β/γ-actin, while histone H3 was only citrullinated by PAD4.
CONCLUSION: These studies identified β and γ-actins as novel citrullinated autoantigens in RA, allowing enzyme specificity against intracellular substrates to be addressed. The studies provide evidence that PAD enzymes have the intrinsic capacity to select unique protein targets. The authors propose that unique PAD specificity may play a role in autoantigen selection in RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859690      PMCID: PMC3302156          DOI: 10.1136/ard.2011.151712

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  36 in total

1.  Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids.

Authors:  Y Takizawa; A Suzuki; T Sawada; M Ohsaka; T Inoue; R Yamada; K Yamamoto
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

2.  Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation.

Authors:  Fabrizio G Mastronardi; D Denise Wood; Jiang Mei; Reinout Raijmakers; Vivian Tseveleki; Hans-Michael Dosch; Lesley Probert; Patrizia Casaccia-Bonnefil; Mario A Moscarello
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

3.  Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis.

Authors:  Andrew Kinloch; Karin Lundberg; Robin Wait; Natalia Wegner; Ngee Han Lim; Albert J W Zendman; Tore Saxne; Vivianne Malmström; Patrick J Venables
Journal:  Arthritis Rheum       Date:  2008-08

4.  Histone deimination as a response to inflammatory stimuli in neutrophils.

Authors:  Indira Neeli; Salar N Khan; Marko Radic
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 5.  PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease.

Authors:  Erik R Vossenaar; Albert J W Zendman; Walther J van Venrooij; Ger J M Pruijn
Journal:  Bioessays       Date:  2003-11       Impact factor: 4.345

6.  Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.

Authors:  Michelle L Harris; Erika Darrah; Gordon K Lam; Susan J Bartlett; Jon T Giles; Audrey V Grant; Peisong Gao; William W Scott; Hani El-Gabalawy; Livia Casciola-Rosen; Kathleen C Barnes; Joan M Bathon; Antony Rosen
Journal:  Arthritis Rheum       Date:  2008-07

7.  Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation.

Authors:  Céline Foulquier; Mireille Sebbag; Cyril Clavel; Sabine Chapuy-Regaud; Roula Al Badine; Marie-Claire Méchin; Christian Vincent; Rachida Nachat; Michiyuki Yamada; Hidenari Takahara; Michel Simon; Marina Guerrin; Guy Serre
Journal:  Arthritis Rheum       Date:  2007-11

8.  Antibodies to citrullinated human fibrinogen synthetic peptides in diagnosing rheumatoid arthritis.

Authors:  María L Pérez; María J Gómara; Guadalupe Ercilla; Raimon Sanmartí; Isabel Haro
Journal:  J Med Chem       Date:  2007-06-23       Impact factor: 7.446

9.  Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages.

Authors:  E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

10.  Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach.

Authors:  Kosuke Matsuo; Yang Xiang; Hiroshi Nakamura; Kayo Masuko; Kazuo Yudoh; Koji Noyori; Kusuki Nishioka; Tomoyuki Saito; Tomohiro Kato
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  76 in total

1.  Uncovering a Shared Epitope-Activated Protein Citrullination Pathway.

Authors:  Vincent van Drongelen; Wahida H Ali; Joseph Holoshitz
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

2.  Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis.

Authors:  Violeta Romero; Justyna Fert-Bober; Peter A Nigrovic; Erika Darrah; Uzma J Haque; David M Lee; Jennifer van Eyk; Antony Rosen; Felipe Andrade
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956

Review 3.  Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation.

Authors:  Erin E Witalison; Paul R Thompson; Lorne J Hofseth
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

4.  Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice.

Authors:  Kimberly Martinod; Melanie Demers; Tobias A Fuchs; Siu Ling Wong; Alexander Brill; Maureen Gallant; Jing Hu; Yanming Wang; Denisa D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

5.  Generation of Distinct Patterns of Rheumatoid Arthritis Autoantigens by Peptidylarginine Deiminase Types 2 and 4 During Perforin-Induced Cell Damage.

Authors:  Violeta Romero; Erika Darrah; Felipe Andrade
Journal:  Arthritis Rheumatol       Date:  2020-04-07       Impact factor: 10.995

6.  Inhibiting protein arginine deiminases has antioxidant consequences.

Authors:  Erin E Witalison; Xiangli Cui; Anne B Hofseth; Venkataraman Subramanian; Corey P Causey; Paul R Thompson; Lorne J Hofseth
Journal:  J Pharmacol Exp Ther       Date:  2015-01-29       Impact factor: 4.030

Review 7.  Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis.

Authors:  V Michael Holers
Journal:  Curr Opin Immunol       Date:  2013-11-08       Impact factor: 7.486

Review 8.  Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions.

Authors:  Clifton O Bingham; Malini Moni
Journal:  Curr Opin Rheumatol       Date:  2013-05       Impact factor: 5.006

Review 9.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

10.  Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation.

Authors:  Mandar Bawadekar; Daeun Shim; Chad J Johnson; Thomas F Warner; Ryan Rebernick; Dres Damgaard; Claus H Nielsen; Ger J M Pruijn; Jeniel E Nett; Miriam A Shelef
Journal:  J Autoimmun       Date:  2017-02-07       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.